Abstract | BACKGROUND: OBJECTIVES: This study evaluated the dose-response of AVE5026 for the prevention of VTE in patients undergoing TKR surgery. PATIENTS/METHODS: In this parallel-group, double-blind, double-dummy study, 690 patients were randomized, and 678 treated with once-daily doses of AVE5026 (5, 10, 20, 40, or 60 mg) or enoxaparin 40 mg in the calibrator arm. The primary efficacy end point was VTE until post-operative day 11, defined as deep vein thrombosis (DVT) detected by bilateral venography, symptomatic DVT, non-fatal pulmonary embolism (PE) and VTE-related death. The primary safety outcome was the incidence of major bleeding. RESULTS: The primary efficacy outcome was assessed in 464 patients. There was a significant dose-response across the five AVE5026 groups for VTE prevention (P<0.0001), with the incidence of VTE ranging from 5.3% to 44.1% compared with 35.8% in the enoxaparin group and for proximal DVT (P=0.0002). Also, a significant dose-response for AVE5026 was seen for major bleeding (P=0.0231) and any bleeding (P=0.0003). Six patients in the AVE5026 groups, four in the 60 mg group, experienced major bleeding; none did in the enoxaparin group. CONCLUSIONS: The safety and efficacy results of this study suggest that a AVE5026 dose of between 20 and 40 mg presents an adequate benefit-to-risk ratio.
|
Authors | M R Lassen, O E Dahl, P Mismetti, D Destrée, A G G Turpie |
Journal | Journal of thrombosis and haemostasis : JTH
(J Thromb Haemost)
Vol. 7
Issue 4
Pg. 566-72
(Apr 2009)
ISSN: 1538-7836 [Electronic] England |
PMID | 19187076
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- AVE 5026
- Heparin, Low-Molecular-Weight
- Heparin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Arthroplasty, Replacement, Knee
(adverse effects)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Hemorrhage
(chemically induced)
- Heparin
(administration & dosage, analogs & derivatives)
- Heparin, Low-Molecular-Weight
(administration & dosage, toxicity)
- Humans
- Male
- Middle Aged
- Postoperative Complications
(prevention & control)
- Premedication
(methods)
- Risk Assessment
- Venous Thromboembolism
(prevention & control)
|